Advances in preclinical therapeutics development using small animal imaging and molecular analyses: The gastrointestinal stromal tumors model

Clinical and Experimental Medicine

Volumn 9, Issue 3, 2009, Pages 199-205

  Pantaleo, M A ^a   Landuzzi, L ^b   Nicoletti, G ^b   Nanni, C ^a   Boschi, S ^a   Piazzi, G ^a   Santini, D ^a   Di Battista, M ^a   Castellucci, P ^a   Lodi, F ^a   Fanti, S ^a   Lollini, P L ^a   Biasco, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

18 Fluoro deoxiglucose (FDG); 18 Fluoro deoxythymidine (FLT); Gastrointestinal stromal tumors (GISTs); Small animal PET; Tyrosine kinase (TK) inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUORODEOXYGLUCOSE F 18; GLUCOSE; SOMATOMEDIN C; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; DISEASE MODEL; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; ANIMAL; DRUG SCREENING; METABOLISM; METHODOLOGY; NUDE MOUSE; TREATMENT OUTCOME; XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL STROMAL TUMORS; GLUCOSE; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 70349787591     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-009-0033-5     Document Type: Article

References (33)

1. S Hirota K Isozaki Y Moriyama K Hashimoto T Nishida S Ishiguro K Kawano M Hanada A Kurata M Takeda G Muhammad Tunio Y Matsuzawa Y Kanakura Y Shinomura Y Kitamura 1998 Gain of function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 9438854 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D (Pubitemid 28067289)
2. ML Lux BP Rubin TL Biase CJ Chen T Maclure G Demetri S Xiao S Singer CD Fletcher JA Fletcher 2000 KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors Am J Pathol 156 791 795 10702394 1:CAS:528:DC%2BD3cXitVerur0%3D
3. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts MC Heinrich DA Tuveson S Singer M Janicek JA Fletcher SG Silverman SL Silberman R Capdeville B Kiese B Peng S Dimitrijevic BJ Druker C Corless CD Fletcher H Joensuu 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours N Engl J Med 347 472 480 12181401 10.1056/NEJMoa020461 1:CAS:528:DC%2BD38XmtV2nt7s%3D (Pubitemid 34879334)
4. GD Demetri AT van Oosteroom CR Garrett ME Blackstein MH Shah J Verweij G McArthur IR Judson MC Heinrich JA Morgan J Desai CD Fletcher S George CL Bello X Huang CM Baum PG Casali 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 17046465 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL (Pubitemid 44528723)
5. H Choi C Charnsangavej SC Faria HA Macapinlac MA Burgess SR Patel LL Chen DA Podoloff RS Benjamin 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 1759 17470865 10.1200/JCO.2006.07.3049 (Pubitemid 46797957)
6. RS Benjamin H Choi HA Macapinlac MA Burgess SR Patel LL Chen DA Podoloff C Charnsangavej 2007 We should desist using RECIST, at least in GIST J Clin Oncol 25 1760 1764 17470866 10.1200/JCO.2006.07.3411 (Pubitemid 46797958)
7. H Barthel MC Cleij DR Collingridge OC Hutchinson S Osman Q He SK Luthra F Brady PM Price EO Aboagye 2003 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography Cancer Res 63 3791 3798 12839975 1:CAS:528:DC%2BD3sXltVGqs78%3D
8. Pantaleo MA, Nannini M, Lopci E, Castellucci P, Maleddu A, Lodi F, Nanni C, Allegri V, Astorino M, Brandi G, Di Battista M, Boschi S, Fanti S, Biasco G (2008) Molecular imaging and targeted therapies in oncology: new concepts of treatment response assessment. A collection of cases. Int J Oncol (in press)
9. P Therasse S Arbuck E Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
10. 18FDG- positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2012 2020 12957455 10.1016/S0959-8049(03) 00073-X 1:CAS:528:DC%2BD3sXmvVKgt74%3D (Pubitemid 37297757)
11. G Antoch J Kanja S Bauer H Kuehl K Renzing-Koehler J Schuette A Bockisch JF Debatin LS Freudenberg 2004 Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumours J Clin Med 45 357 365 1:CAS:528: DC%2BD2cXivVCjur0%3D
12. GW Goerres R Stupp G Barghouth TF Hany B Pestalozzi E Dizendorf P Schnyder F Luthi GK von Schulthess S Leyvraz 2005 The value of PET, CT, and in line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging 32 153 162 15690223 10.1007/s00259-004-1633-7 1:CAS:528:DC%2BD2MXpsFyktQ%3D%3D (Pubitemid 40248485)
13. AD Van den Abbeele 2008 The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 suppl2 8 13 18434632 10.1634/theoncologist. 13-S2-8
14. C Nanni D Rubello S Fanti 2007 Role of small animal PET for molecular imaging in pre-clinical studies Eur J Nucl Med Mol Imaging 34 1819 1822 17351773 10.1007/s00259-007-0394-5 (Pubitemid 47599044)
15. DS Boss RV Olmos M Sinaasappel JH Beijnen JH Schellens 2008 Application of PET/CT in the development of novel anticancer drugs Oncologist 13 25 38 18245010 10.1634/theoncologist.2007-0097 1:CAS:528:DC%2BD1cXivFGrt7w%3D (Pubitemid 351206694)
16. S Greschus F Kiessling MP Lichy J Moll MM Mueller R Savai F Rose C Ruppert A Günther M Luecke NE Fusenig W Semmler H Traupe 2005 Potential applications of flat-panel volumetric CT in morphologic and functional small animal imaging Neoplasia 7 730 740 16207475 10.1593/neo.05160
17. CP Reynolds BC Sun YA DeClerek RA Moats 2005 Assessing growth and response to therapy in murine tumor models Methods Mol Med 111 335 350 15911989 1:CAS:528:DC%2BD2MXkt1Cqsbs%3D
18. C Cullinane DS Dorow M Kansara N Conus D Binns RJ Hicks LK Ashman GA McArthur DM Thomas 2005 An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development Cancer Res 65 9633 9636 16266981 10.1158/0008-5472.CAN-05-2285 1:CAS:528:DC%2BD2MXhtFKkt7nM (Pubitemid 41541437)
19. H Prenen C Deroose P Vermaelen R Sciot M Debiec-Rychter S Stroobants L Mortelmans P Schöffski A Van Oosterom 2006 Establishment of a mouse gastrointestinal stromal tumor model and evaluation of response to imatinib by small animal positron emission tomography Anti cancer Res 26 1247 1252 1:CAS:528:DC%2BD28XktFWmsbc%3D
20. KE Kil YS Ding KS Lin D Alexoff SW Kim C Shea Y Xu L Muench JS Fowler 2007 Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec) Nucl Med Biol 34 153 163 17307123 10.1016/j.nucmedbio.2006. 11.004 1:CAS:528:DC%2BD2sXhvVOqtrs%3D (Pubitemid 46251643)
21. Liegl B, Kepten I, Le C, Zhu M, Demetri G, Heinrich M, Fletcher C, Corless C, Fletcher J (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216:64-74
22. H Wang W Cai K Chen ZB Li A Kashefi L He X Chen 2007 A new PET tracer specific for vascular endothelial growth factor receptor 2 Eur J Nucl Med Mol Imaging 34 2001 2010 17694307 10.1007/s00259-007-0524-0 1:CAS:528: DC%2BD2sXhtlyiurrP (Pubitemid 350212131)
23. MC Heinrich CL Corless GD Demetri CD Blanke M von Mehren H Joensuu LS McGreevey CJ Chen AD Van den Abbeele BJ Druker B Kiese B Eisenberg PJ Roberts S Singer CD Fletcher S Silberman S Dimitrijevic JA Fletcher 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 4342 4349 14645423 10.1200/JCO.2003.04.190 1:CAS:528: DC%2BD2cXpsVWqu7Y%3D (Pubitemid 46621810)
24. MC Heinrich RG Maki CL Corless CR Antonescu A Harlow D Griffith A Town A McKinley WB Ou JA Fletcher CD Fletcher X Huang DP Cohen CM Baum GD Demetri 2008 Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor J Clin Oncol 33 5352 5359 10.1200/JCO.2007.15.7461
25. CR Antonescu P Besmer T Guo K Arkun G Hom B Koryotowski MA Leversha PD Jeffrey D Desantis S Singer MF Brennan RG Maki RP DeMatteo 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182 4190 15930355 10.1158/1078-0432.CCR-04-2245 1:CAS:528:DC%2BD2MXks1GksLw%3D (Pubitemid 40791584)
26. MC Heinrich CL Corless CD Blanke GD Demetri H Joensuu PJ Roberts BL Eisenberg M von Mehren CD Fletcher K Sandau K McDougall WB Ou CJ Chen JA Fletcher 2006 Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 4764 4774 16954519 10.1200/JCO.2006.06.2265 1:CAS:528:DC%2BD28XhtFynsrrN (Pubitemid 46630941)
27. N Nakai T Ishikawa A Nishitani NN Liu M Shincho H Hao K Isozaki T Kanda T Nishida J Fujimoto S Hirota 2008 A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy J Pathol 214 302 311 18098338 10.1002/path.2296 1:CAS:528:DC%2BD1cXivVSgt70%3D (Pubitemid 351212385)
28. BP Rubin CR Antonescu JP Scott-Browne ML Comstock Y Gu MR Tanas CB Ware J Woodell 2005 A knock-in mouse model of gastrointestinal stromal tumors harboring kit K641E Cancer Res 65 6631 6639 16061643 10.1158/0008-5472.CAN-05- 0891 1:CAS:528:DC%2BD2MXmvFSlt78%3D (Pubitemid 41060699)
29. G Sommer V Agosti I Ehlers F Rossi S Corbacioglu J Farkas M Moore K Manova CR Antonescu P Besmer 2003 Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase Proc Natl Acad Sci USA 100 6706 6711 12754375 10.1073/pnas.1037763100 1:CAS:528: DC%2BD3sXktlygsLw%3D (Pubitemid 36666644)
30. F Rossi I Ehlers V Agosti ND Socci A Viale G Sommer Y Yozgat K Manova CR Antonescu P Besmer 2006 Oncogenic KIT signalling and therapeutic intervention in a mouse model of gastrointestinal stromal tumors Proc Natl Acad Sci USA 103 12843 12848 16908864 10.1073/pnas.0511076103 1:CAS:528:DC%2BD28XptVymtrg%3D (Pubitemid 44298649)
31. B Gunawam 2008 Knock-in murine models of familial gastrointestinal stromal tumours J Pathol 214 407 409 10.1002/path.2315 (Pubitemid 351340560)
32. CR Antonescu A Viale L Sarran SJ Tschernyavsky M Gonen NH Segal RG Maki ND Socci RP DeMatteo P Besmer 2004 Gene expression in gastrointestinal stromal tumours is distinguished by KIT genotype and anatomic site Clin Cnacer Res 10 3282 3290 10.1158/1078-0432.CCR-03-0715 1:CAS:528:DC%2BD2cXkt1Ghs70%3D (Pubitemid 38685432)
33. LA Meza-Zepeda SH Kresse AH Barragan-Polania B Bjerkehagen HO Ohnstad HM Namløs J Wang BE Kristiansen O Myklebost 2006 Array comaparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomiosarcomas Cancer Res 66 8984 8993 16982739 10.1158/0008-5472.CAN-06-1972 1:CAS:528:DC%2BD28Xps1aitb8%3D (Pubitemid 44521116)